Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry - 1 May 2011

Lenze Eric J, Mantella Rose C, Shi Peichang, Goate Alison M, Nowotny Petra, Butters Meryl A, Andreescu Carmen, Thompson Paul A, Rollman Bruce L

Abstract excerpt

BACKGROUND: Generalized anxiety disorder (GAD) is a common disorder in older adults, which has been linked to hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in this age group. The authors examined whether treatment of GAD in older adults with a selective serotonin reuptake inhibitor (SSRI) corrects this HPA axis hyperactivity. METHODS: The authors examined adults aged 60 years and older with GAD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anxiety Disorders
Share to Citalopram

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrocortisone

Share to Hypothalamo-Hypophyseal System

Share to Pituitary-Adrenal System

Share to Saliva

Share to Selective Serotonin Reuptake Inhibitors

Share to Serotonin Plasma Membrane Transport Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 20808146
DOI: 10.1097/JGP.0b013e3181ec806c
PMCID: PMC3424606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram.PMID 20808146Read ↗

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.Semantic proximity Read ↗

Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors.Semantic proximity Read ↗

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.Semantic proximity Read ↗

The effectiveness of using escitalopram in pediatric generalized anxiety disorder and the methods to predict the treatment response: A systematic review and meta-analysisSemantic proximity Read ↗

Oxidative stress markers predict treatment outcomes in patients with generalized anxiety disorder treated with selective serotonin reuptake inhibitorsSemantic proximity Read ↗

Common functional mineralocorticoid receptor polymorphisms modulate the cortisol awakening response: Interaction with SSRIs.Semantic proximity Read ↗

Age-dependent association of polymorphisms in the promoter and 5'-untranslated region of the norepinephrine transporter gene with generalized anxiety disorder.Semantic proximity Read ↗

Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response.Semantic proximity Read ↗

Baseline serum oxytocin and OXTR rs53576 genotype are not predictive of escitalopram response in generalized anxiety disorder.Semantic proximity Read ↗

Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity Read ↗

Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity Read ↗

Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.